The von Hippel-Lindau tumor suppressor gene: A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis

Cancer Genetics and Cytogenetics

Volumn 93, Issue 1, 1997, Pages 74-83

  Decker, H J H ^a   Weidt, E J ^a   Brieger, J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

ADULT; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENES, TUMOR SUPPRESSOR; GENOTYPE; GERM-LINE MUTATION; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; LIGASES; MALE; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROTEINS; RETINA; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

LONCHOCARPUS GLAUCIFOLIUS;

EID: 0031047993     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(96)00296-8     Document Type: Article

References (127)

1. 1. Nelson NJ. (1995): Old protein, new function: VHL tumor suppressor protein inhibits transcription. J Natl Cancer Inst 87:1432-1433.
2. 2. Krumm A, Groudine M (1995): Tumor suppression and transcription elongation: The dire consequences of changing partners. Science 269:1400-1401.
3. 3. Gnarra JR, Lerman MI, Zbar B, Linehan WM (1995): Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22:3-8.
4. 4. Linehan WM, Lerman MI, Zbar B (1995): Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273:564-570.
5. 5. Neumann HP, Lips CJ, Hsia YE, Zbar B (1995): Von Hippel-Lindau syndrome. Brain Pathol 5:181-193.
6. 6. Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM (1996): Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1242: 201-210.
7. 7. Decker HJ, Bauer C, Speicher M, Ried T, Bujard M. Brauch H, Störkel S, Stöckle M, Cremer T, Huber C (1996): Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study including Cytogenetics, SSCP, FISH, and CGH. Hum Genet 97: 770-776.
8. 8. Richards FM, Crossey PA, Phipps ME, Foster K, Latif F, Evans GA, Sampson J, Lerman M, Zbar B, Affara NA (1994): Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum Mol Genet 3:595-598.
9. 9. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman M, Zbar B, Affara NA, Ferguson-Smith MA (1994): Identification of intragenic mutations in the Von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3:1303-1308.
10. 10. Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Höfler H, Latif F, Lerman M, Zbar B, Neumann HPH (1995): von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: Evidence for a founder effect. Hum Genet 95:551-556.
11. 11. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra J, Orcutt L, Duh FM, Glenn G (1995): Germline mutation in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat 5:66-75.
12. 12. Neumann HP, Eng C, Mulligan LM, Glavac D, Zauner I, Ponder BA, Crossey PA, Maher ER, Brauch H (1995): Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 274:1149-1151.
13. 13. Maddock IR, Moran A, Maher ER, Teare MD, Norman A, Payne SJ, Whitehouse R, Dodd C, Lavin M, Hartley N (1996): A genetic register for von Hippel-Lindau disease. J Med Genet 33:120-127.
14. 14. Aso T, Lane WS, Conaway JW, Conaway RC (1995): Elongin (SIII): A multisubunit regulator of elongation by RNA polymerase II. Science 269:1439-1443.
15. 15. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG, Jr (1995): Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269:1444-1446.
16. 16. Duan DR, Pause A, Burgess WH, Aso T, Chen DH, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD (1995): Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402-1406.
17. 17. von Hippel E (1904): Über eine sehr seltene Erkrankung der Netzhaut, v Graefe's Arch Ophthal 59.83.
18. 18. von Hippel E (1895): Vorstellung eines Patienten mit einem sehr ungewöhnlichen Netzhaut-bzw. Aderhautleiden. Ber dtsch ophthal Ces 24:269.
19. 19. von Hippel E (1911): Die anatomische Grundlage der von mir beschriebenen "sehr seltenen Erkrankung der Netzhaut" von Graefe Arch Ophthal 79:350-377.
20. 20. Lindau A (1926): Studien über Kleinhirncysten. Bau, Pathogenese und Beziehung zur Angiomatosis retinae. Acta pathol microbiol scand 1.
21. 21. Melmon KL, Rosen SW (1964): Lindau's Disease. Review of the Literature and Study of a Large Kindred. Am J Med 36:595-617.
22. 22. Horton WA, Wong V, Eldrigde R (1976): Von Hippel-Lindau Disease. Clinical and Pathological Manifestations in Nine Families With 50 Affected Members. Arch Intern Med 136:769-777.
23. 23. Green JS, Bowmer MI, Johnson GJ (1986): Von Hippel-Lindau disease in a Newfoundland kindred. Can Med Assoc J 134: 133-138.
24. 24. Lamiell JM, Salazar FG, Hsia YE (1989): von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 68:1-29.
25. 25. Mäher ER (1994): Von Hippel-Lindau disease. Eur J Cancer 30A:1987-1990.
26. 26. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JW, Collins D, Majoor Krakauer D (1988): Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332:268-269.
27. 27. Hosoe S, Brauch H, Latif F, Glenn G, Daniel L, Bale S, Choyke P, Gorin M, Oldfield E, Berman A (1990): Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 8:634-640.
28. 28. Vance JM, Small KW, Jones MA, Stajich JM, Yamaoka LH, Roses AD, Hung WY, Pericak Vance MA (1990): Confirmation of linkage in von Hippel-Lindau disease. Genomics 6:565-567.
29. 29. Tory K, Latif F, Modi W, Schmidt L, Wei MH, Li H, Cobler P, Orcutt ML, Delisio J, Geil L (1992): A Genetic Linkage Map of 96 Loci on the Short Arm of Human Chromosome 3. Genomics 13:275-286.
30. 30. Pericak-Vance MA, Nunes KJ, Whisenant E, Loeb DB, Small KW, Staijach JM, Rimmler JB, Yamaoka LH, Smith DI, Drabkin HA, Vance JM (1993) Genetic mapping of dinucleotide repeat polymorphisms and von Hippel-Lindau disease on chromosome 3p25-26. Med Genet 30:487-491.
31. 31. Crossey PA, Maher ER, Jones MH, Richards FM, Latif F, Phillips ME, Lush M, Foster K, Tory K, Green JS (1993): Genetic linkage between Von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus. Hum Mol Genet 2(3):279-282.
32. 32. Seizinger BR, Smith DI, Filling-Katz MR, Neumann H, Green JS, Choyke PL, Anderson KM, Freiman RN, Klauck SM, Whaley J, Decker HJH, Hsia YE, Collins D (1991): Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease. Proc Natl Acad Sci USA 88:2864-2868.
33. 33. King CR, Schimke RN, Arthur T, Davoren B, Collins D (1987): Proximal 3p deletion in renal cell carcinoma cells from a patient with von Hippel-Lindau disease. Cancer Genet Cytogenet 27:345-348.
34. 34. Decker HJ, Neumann HP, Walter TA, Sandberg AA (1988): 3p involvement in a renal cell carcinoma in von Hippel-Lindau syndrome. Region of tumor breakpoint clustering on 3p. Cancer Genet Cytogenet 33:59-65.
35. 35. Kiechle-Schwarz M, Neumann HP, Decker HJ, Dietrich C, Wullich B, Schempp W (1989): Cytogenetic studies on three pheochromocytomas derived from patients with von Hippel-Lindau syndrome. Hum Genet 82:127-130.
36. 36. Bergerheim US, Frisk B, Stellen B, Collins VP, Zech L (1990): del(3p)(p13p21) in renal cell adenoma and del(4p)(p14) in bilateral renal cell carcinoma in two unrelated patients with von Hippel-Lindau disease. Cancer Genet Cytogenet 49:125-131.
37. 37. Jordan DK, Patil SR, Divelbiss JE, Vemuganti S, Headley C, Waziri MH, Gurll NJ (1989): Cytogenetic abnormalities in tumors of patients with von Hippel-Lindau disease. Cancer Genet Cytogenet 42:227-241.
38. 38. Kovacs G, Kung HF (1991): Nonhomologous chromatid exchange in hereditary and sporadic renal cell carinomas. Proc Natl Acad Sci USA 88:194-198.
39. 39. Goodman MD, Goodman BK, Lubin MB, Braunstein G, Rotter JI, Schreck RR (1990): Cytogenetic characterization of renal cell carcinoma in von Hippel-Lindau syndrome. Cancer 65:1150-1154.
40. 40. Kovacs G, Emanuel A, Neumann HP, Kung HF (1991): Cytogenetics of renal cell carcinomas associated with von Hippel-Lindau disease. Genes Chrom Cancer 4:256-262.
41. 41. Decker HJ, Klauck SM, Lawrence JB, McNeil J, Smith D, Gemmill RM, Sandberg AA, Neumann HH, Simon B, Green J, Seizinger BR (1994): Cytogenetic and fluorescence in situ hybridization studies on sporadic and hereditary tumors associated with von Hippel-Lindau syndrome (VHL). Cancer Genet Cytogenet 77:1-13.
42. 42. Decker HJ, Gemmill RM, Neumann HP, Walter TA, Sandberg AA (1989): Loss of heterozygosity on 3p in a renal cell carcinoma in von Hippel-Lindau syndrome. Cancer Genet Cytogenet 39:289-293.
43. 43. Tory K, Bruch H, Linehan M, Barba D, Oldfield E, Filling-Katz M, Seizinger B, Nakamura Y, White R, Marshall FF, Lerman IL, Zbar B (1989): Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81:1097-1101.
44. 44. Crossey PA, Foster K, Richards FM, Phipps ME, Latif F, Tory K, Jones M, Bentley E, Kumar R, Lerman M, Zbar B, Affara NA, Ferguson-Smith MA, Maher ER, Jones MH, Lerman MI (1994): Molecular genetic investigations of the mechanism of tumorigenesis in von Hippel-Lindau disease: Analysis of allele loss in VHL tumours. Hum Genet 93: 53-58.
45. 45 Latif F, Duh FM, Gnarra J, Tory K, Kuzmin I, Yao M, Stackhouse T, Modi W, Geil L, Schmidt L, Li H, Orcutt ML, Maher E, Richards F, Phipps M, Ferguson-Smith M, Le Paslier D, Linehan WM, Zbar B, Lerman MI (1993): von Hippel-Lindau syndrome: Cloning and identification of the plasma membrane Ca(++)-transporting ATPase isoform 2 gene that resides in the von Hippel-Lindau gene region. Cancer Res 53:861-867.
46. 46. Liu W, Piechocki M, Shridhar V, Lyles G, Song Z, Nakamura Y, Drabkin H, Vance J, Smith DI (1993): The isolation of a yeast artificial chromosome (YAC) contig extending for 2 megabases in the vicinity of the von Hippel Lindau disease gene. Hum Mol Genet 2:1177-1182.
47. 47. Zbar B, Brauch H, Talmadge C, Linehan M (1987): Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327:721-724.
48. 48. Maher ER, Bentley E, Yates JR, Latif F, Lerman M, Zbar B, Affara NA, Ferguson-Smith MA (1991): Mapping of the von Hippel-Lindau disease locus to a small region of chromosome 3p by genetic linkage analysis. Genomics 10:957-960.
49. 49. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG (1995): Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269:1444-1446.
50. 50. Wizigmann Voos S, Breier G, Risau W, Plate KH (1995): Upregulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55:1358-1364.
51. 51. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marmé D (1996): Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299-2301.
52. 52. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, Sampson J, Williams A, Ferguson-Smith MA, Morton N (1991): von Hippel-Lindau disease: A genetic study. J Med Genet 28:443-447.
53. 53. Neumann HPH, Schempp W, Wienker TF (1987) High resolution chromosome banding and fragile site studies in von Hippel-Lindau syndrome. Cancer Genet Cytogenet 31:41-46.
54. 54. Neumann HP, Wiestler OD (1991): Clustering of features of von Hippel-Lindau syndrome: Evidence for a complex genetic locus. Lancet 337:1052-1054.
55. 55. Maher ER. Von Hippel-Lindau disease (1993) In: Hodgson SV, Maher ER. A practical guide to human cancer genetics. Cambridge University Press, Cambridge, pp. 157-162.
56. 56. Zlotogora J (1993): Mutations in von Recklinghausen neurofibromatosis: an hypothesis. Am J Med Genet 46:182-184.
57. 57. Glavac D, Neumann HPH, Wittke C, Jaenig H, Masek O, Streicher T, Pausch F, Engelhardt D, Plate KH, Höfler H, Chen F, Zbar B, Brauch H (1996): Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central europe. Hum Genet 99:271-280.
58. 58. Richards FM, Payne SJ, Zbar B, Affara NA, Ferguson Smith MA, Maher ER (1995): Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 4 11.2139-2143.
59. 59. Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA (1990): Clinical features and natural history of von Hippel-Lindau Disease. Q J Med 77(203):1151-1163.
60. 60. Davies DR, Norman AM, Whitehouse RW, Evans DG (1994): Non-expression of von Hippel-Lindau phenotype in an obligate gene carrier. Clin Genet 45:104-106.
61. 61. Glenn GM, Daniel LN, Choyke P, Linehan WM, Oldfield E, Gorin MB, Hosoe S, Latif F, Weiss G, Walther M, Lerman MI, and Zbar B (1991): von Hippel-Lindau (VHL) disease: Distinct phenotypes suggest more than one mutant allele at the VHL locus. Hum Genet 87:207-210.
62. 62. Maher ER, Yates JR, Ferguson Smith MA, (1990): Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet 27:311-314.
63. 63. Knudson AG (1971): Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
64. 64. Solomon D, Schwartz A (1996): Renal pathology in von Hippel-Lindau disease. Hum Pathol 19:1072-1079.
65. 65. Christenson PJ, Craig JP, Bibro MC, O'Connell P (1982): Cysts containing renal cell carcinoma in von Hippel-Lindau disease. J Urol 128:798-800.
66. 66. Malek RS, Omess PJ, Benson RC, Zincke H (1987): Renal cell carcinoma in von Hippel-Lindau syndrome. Am J Med 82:236-238.
67. 67. Ibrahim RE, Weinberg DS, Weidner N (1989): Atypical cysts and carcinoma of the kidneys in the phacomatoses. Cancer 63:148-157.
68. 68. Poston CD, Jaffe GS, Lubensky IA, Solomon D, Zbar B, Linehan WM, Walther MM (1995): Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: Clinical and molecular genetic implications. J Urol 153:22-26.
69. 69. Spencer WF, Novick AC, Montie JE, Streem SB, Levin HS (1988): Surgical treatment of localized renal cell carcinoma in von Hippel-Lindau's disease. J Urol 139:507-509.
70. 70. Choyke PL (1994): Radiology of Visceral VHL lesions. [Abstract]. In: International Symposium von Hippel-Lindau Syndrome, Freiburg.
71. 71. Hough DM, Stephens DH, Johnson CD, Binkovitz LA (1994): Pancreatic lesions in von Hippel-Lindau disease: Prevalence, clinical significance, and CT findings. AJR 162:1091-1094.
72. 72. Blamires TL, Maher ER (1992): Choroid plexus papilloma. A new presentation of von Hippel-Lindau (VHL) disease. Eye 6:90-92.
73. 73. Neumann HP (1991): Das v. Hippel-Lindau-Syndrom. (The von Hippel-Lindau syndrome). Dtsch Med Wschr 116:28-34.
74. 74. Neumann HP (1987): Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa 16:220-226.
75. 75. Maher ER, Bentley E, Payne SJ, Latif F, Richards FM, Chiano M, Hosoe S, Yates JR, Linehan M, Barton DE, and others (1992): Presymptomatic diagnosis of von Hippel-Lindau disease with flanking DNA markers. J Med Genet 29:902-905.
76. 76. Glenn GM, Linehan WM, Hosoe S, Latif F, Yao M, Choyke P, Gorin MB, Chew E, Olfield E, Manolatos C, Orcutt ML, Walther MM, Weiss GH, Tory K, Lerman MI, Zbar B (1992): Screening for von Hippel-Lindau disease by DNA polymorphism analysis. JAMA 267:1226-1231.
77. 77. Brauch H, Glavac D, Pausch F, Höfler H, Neumann HPH (1995): Genotype-phenotype correlations in families with von Hippel-Lindau disease: Missense mutation at codon 169 correlates with the development of pheochromocytoma. Verh Dtsch Ges Path 79:511.
78. 78. Yao M, Latif F, Orcutt ML, Kuzmin I, Stackhouse T, Zhou FW, Tory K, Duh FM, Richards F, Maher E, and others (1993): von Hippel-Lindau disease: Identification of deletion mutations by pulsed-field gel electrophoresis. Hum Genet 92:605-614.
79. 79. Richards FM, Phipps ME, Latif F, Yao M, Crossey PA, Foster K, Linehan WM, Affara NA, Lerman MI, Zbar B, and others. (1993): Mapping the Von Hippel-Lindau disease tumour suppressor gene: Identification germline deletions by pulsed field gel electrophoresis. Hum Mol Genet 2, 7:879-882.
80. 80. Klauck SM, Whisenanf E, Wood M, Drabkin HA, Seizinger BR (1994): Dinucleotide repeat polymorphism at the D3S1255 locus. Hum Mol Gen 3:840.
81. 81. Neumann HPH, Berger DP, Sigmund G (1993): Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329:1531-1538.
82. 82. Weither MM, Lubensky IA, Venzon D, Zbar B, Linehan WM (1995): Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: Clinical implications. J Urol 154:2010-2014.
83. 83. Kovacs G (1990): Application of molecular cytogenetic techniques to the evaluation of renal parenchymal tumors. J Cancer Res Clin Oncol 116:318-323.
84. 84. Novick AC (1992): The role of renal-sparing surgery for renal cell carcinoma. Semin Urol 10:12-15.
85. 85. Shinohara N, Nonomura K, Harabayashi T, Togashi M, Nagamori S, Koyanagi T (1995): Nephron sparing surgery for renal cell carcinoma in von Hippel-Lindau disease. J Urol 154:2016-2019.
86. 86. Lund GO, Fallon BF, Curtis MA, Williams RD (1994); Conservative surgical therapy of localized renal cell carcinoma in von Hippel-Lindau disease. Cancer 74:2541-2545.
87. 87. Steinbach F, Novick AC, Shoskes D (1994): Renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Urology 44:760-763.
88. 88. Schmidt D, Neumann HP (1995): Retinal vascular hamartoma in von Hippel-Lindau disease. Arch Ophthalmol 113: 1163-1167.
89. 89. Resche F, Moisan JP, Mantoura J, De Kersaint Gilly A (1993): Haemangioblastoma, haemangioblastomatosis and von Hippel-Lindau disease. Adv Techn Stand Neurosurg 20: 197-204.
90. 90. Obara T, Kanbe M, Okamoto T, Ito Y, Yamashita T, Ito K, Hirose K, Yamazaki K, Hagihara J, Kusakabe K (1995): Surgical strategy for pheochromocytoma: Emphasis on the pledge of flank extraperitoneal approach in selected patients. Surgery 118:1083-1089.
91. 91. Latif F, Tory K, Gnarra J, Masahiro Y, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L (1993): Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320.
92. 92. Kuzmin I, Stackhouse T, Latif F, Duh FM, Geil L, Gnarra J, Yao M, Orcutt ML, Li H, Tory K (1994): One-megabase yeast artificial chromosome and 400-kilobase cosmid-phage contigs containing the von Hippel-Lindau tumor suppressor and Ca(2+)-transporting adenosine triphosphatase isoform 2 genes. Cancer Res 54:2486-2491.
93. 93. Kuzmin I, Duh FM, Latif F, Geil L, Zbar B, Lerman MI (1995): Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene 10: 2185-2194.
94. 94. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, and others (1994): Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90.
95. 95. Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr (1995): Tumour suppression by the human von Hippel-Lindau gene product. Nature Med 1:822-826.
96. 96. Kishida T, Yao M, Chen F, Orcutt ML, Lerman MI, Zbar B (1994): A novel donor splice site mutation associated with two mRNAs in von Hippel-Lindau disease. Hum Mol Genet 3:1191-1192.
97. 97. Loeb DB, Pericak-Vance MA, Stajiach JM, Vance JM (1994): A novel mutation in the von Hippel-Lindau gene. Hum Mol Genet 3:1423-1424.
98. 98. Whaley JM, Naglich J, Gelbert L, Hsia YE, Lamiell JM, Green JS, Collins D, Neumann HP, Laidlaw J, Li FP, (1994): Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55: 1092-1102.
99. 99. Shuin T, Kondo K, Kaneko S, Sakai N, Yao M, Hosaka M, Kanno H, Ito S, Yamamoto I (1995): Results of mutation analyses of von Hippel-Lindau disease gene in Japanese patients: comparison with results in United States and United Kingdom. Hinyokika Kiyo 41:703-707.
100. 100. Yamakawa K, Morita R, Takahashi E, Hori T, Ishikawa J, Nakamura Y (1991): A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma. Cancer Res 51:4707-4711.
101. 101. Wilhelm M, Bugert P, Kenck C, Stahler G, Kovacs G (1995): Terminal deletion of chromosome 3p sequences in nonpapillary renal cell carcinomas: A breakpoint cluster between loci D3S1285 and D3S1603. Cancer Res 55:5383-5385.
102. 102. Morita R, Ishikawa J, Tsutsumi M, Hikiji K, Tsukada Y, Kamidono S, Maeda S, Nakamura Y (1991): Allelotype of renal cell carcinoma. Cancer Res 51:820-823.
103. 103. Lubinski J, Hadaczek P, Podolski J, Toloczko A, Sikorski A, McCue P, Druck T, Huebner K (1994): Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. Cancer Res 54:3710-3713.
104. 104. Bailly M, Bain C, Favrot MC, Ozturk M (1995): Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers. Int J Cancer 63:660-664.
105. 105. Glavac D, Ravnik-Glavac M, Ovcak Z, Masera A, Brauch H (1996): Genetic changes in the origin and development of renal cell carcinoma (RCC). Eur J Physiol (in press).
106. 106. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zhar B (1994): Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852-2855.
107. 107. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA (1994): Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3:2169-2173.
108. 108. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, and others (1994): Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700-9704.
109. 109. Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe S, Sakai N, Hosaka M, Shuin T, Yao M (1994): Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 54:4845-4847.
110. 110. Eng C, Crossey PA, Mulligan LM, Healy CS, Houghton DC (1995): Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Clin Genet 32:934-937.
111. 111. Gilcrease MZ, Schmidt L, Zbar B, Truong L, Rutledge M, Wheeler TM (1995): Somatic von Hippel Lindau mutation in clear cell papillary cystadenoma of the epididymis. Human Pathol 26:1341-1346.
112. 112. Sekido Y, Bader S, Latif F, Gnarra JR, Gazdar AF, Linehan WM, Zbar B, Lerman MI, Minna JD (1994): Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 9:1599-1604.
113. 113. Stackhouse TM, Lerman M, Zbar B (1995): An in vitro analysis of the von Hippel-Lindau tumor suppressor protein. In: Proc Am Assoc Cancer Res 36:570.
114. 114. Duan DR, Humphrey JS, Chen DY, Weng Y, Sukegawa J, Lee S, Gnarra JR, Linehan WM, Klausner RD (1995): Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 92:6459-6463.
115. 115. Lee S, Chen DYT, Humphrey JS, Klausner RD (1996): Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci USA 93:1770-1775.
116. 116. Kley N, Gavin B, Gao J, Whaley J, Naglich J, Seizinger BR (1996): Characterization of the VHL tumor suppressor gene and VHL knock-out mice. [Abstract]. In: Second International VHL Symposium: 22.
117. 117. Gao J, Naglich J, Laidlaw J, Whaley JM, Seizinger BR, Kley N, Naglich JG (1995): Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: Implications for the potential organization of the human von Hippel-Lindau gene. Cancer Res 55:743-747.
118. 118. Chen F, Kishida T, Duh FM, Renbaum P, Orcutt ML, Schmidt L, Zbar B (1995): Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 55:4804-4807.
119. 119. Shimizu M, Yokota J, Mori N, Shuin T, Shinoda M, Terada M, Oshimura M (1990): Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. Oncogene 5:185-194.
120. 120. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B (1995): Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations. Cancer Res 55:4544-4548.
121. 121. Kolch W, Martiny Baron G, Kieser A, Marme D, Ikeda E, Achen MG, Breier G, Risau W (1995): Regulation of the expression of the VEGF/VPS and its receptors: Role in tumor angiogenesis Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. Breast Cancer Res Treat 270:19761-19766.
122. 122. Weidner N, Folkman J (1996): Tumoral Vascularity as a Prognostic Factor in Cancer. In: De-Vita V, Hellman S, Rosenberg SA. Important advances in oncology. Lippincott-Raven, Philadelphia, pp. 167-190.
123. 123. Shweiki D, Neeman M, Itin A, Keshet E (1996): Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc Natl Acad Sci USA 92: 768-772.
124. 124. Ikeda E, Achen MG, Breier G, Risau W (1995): Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270:19761-19766.
125. 125. Takahashi A, Sasaki H, Kim SJ, Tobisu KI, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M (1994): Markedly increased amounts of messenger RNAs for vascular endothelial associated factor and placenta growth factor in renal cell carcinoma associated angiogenesis. Cancer Res 54:4233-4237.
126. 126. Kaelin W (1996): Functional-Analysis of the von Hippel-Lindau Gene Product [Abstract]. In: Second International VHL Symposium: A 501.
127. 127. Tsuchiya H, Iseda T, Hino O (1996): Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res 56:2881-2885.